Wick, Wolfgang
Weller, Michael
van den Bent, Martin
Sanson, Marc
Weiler, Markus
von Deimling, Andreas
Plass, Christoph
Hegi, Monika
Platten, Michael
Reifenberger, Guido
Article History
First Online: 10 June 2014
Competing interests
: W.W. has received consulting and lecture fees from MagForce, Merck Sharp & Dohme, and Roche, and research support from Apogenix, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme and Roche. He also serves on the Steering Committees of the AVAglio and CENTRIC trials, and is lead investigator of other trials in glioma. M. Weller has received research grants from Isarna Therapeutics, Bayer, Merck Serono, Merck Sharp & Dohme and Roche, and honoraria for lectures or advisory boards from Isarna Therapeutics, MagForce, Merck Serono, Merck Sharp & Dohme and Roche. M.v.d.B. acts as a consultant and is a member of the speakers' bureau for Merck Sharp & Dohme. M.S. has received honoraria from Merck Serono. M.H. has acted as a consultant for MDx Health, Merck Serono, Merck Sharp & Dohme and Roche. M.P. has received consultancy and lecture fees from Medac, Merck Serono, and Novartis, and research support from Merck Serono and Novartis. G.R. has received a research grant from Roche, and honoraria from Merck Serono and Roche. The other authors declare no competing interests.